Overview

A Phase 1 Safety and PK Study of IV TP-271

Status:
Unknown status

Trial end date:
2019-02-28

Target enrollment:

Participant gender:

Summary

This is a single-center, randomized, placebo-controlled, double-blind, multiple-ascending-dose, inpatient study to assess the safety, tolerability, and pharmacokinetics of TP-271 in healthy subjects. Subjects aged 18 to 50 years who fulfill the inclusion/exclusion criteria will be enrolled in this study.

Phase:

Phase 1

Details

Lead Sponsor:

Tetraphase Pharmaceuticals, Inc.

Collaborator:

National Institute of Allergy and Infectious Diseases (NIAID)